Log in

Relevant bibliographies by topics / Daunorubicin / Journal articles

To see the other types of publications on this topic, follow the link: Daunorubicin.

Journal articles on the topic 'Daunorubicin'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Daunorubicin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Drevin, Guillaume, Marie Briet, Caroline Bazzoli, et al. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial." Pharmaceutics 14, no. 4 (2022): 792. http://dx.doi.org/10.3390/pharmaceutics14040792.

Full text

Abstract:

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6–8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m2/day). Daunorubicin and daunorubicinol quantifications were assessed using a validated liq

APA, Harvard, Vancouver, ISO, and other styles

2

Zucchetti, Massimo, Amerigo Boiardi, Antonio Silvani, Idria Parisi, Stefano Piccolrovazzi, and Maurizio D'Incalci. "Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin." Cancer Chemotherapy and Pharmacology 44, no. 2 (1999): 173–76. http://dx.doi.org/10.1007/s002800050964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Daunorubicin see Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 354 (1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Choi, Min-Koo, Im-Sook Song, Dae-Duk Kim, Suk-Jae Chung, and Chang-Koo Shim. "Altered Pharmacokinetics of Daunorubicin in Rats with CCl4-Induced Hepatic Injury." Journal of Pharmacy & Pharmaceutical Sciences 10, no. 4 (2007): 443. http://dx.doi.org/10.18433/j3mw28.

Full text

Abstract:

PURPOSE. The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug. METHODS. CCl4-EHI was induced in rats by a single intraperitoneal injection of CCl4 (1mL/kg rat), and a 24 h fasting period. Daunorubicin was administered intravenously to control and EHI rats at a dose of 11.3 mg/mL/kg and the in vivo pharmacokinetics was studied. The in vitro uptake of the drug into isolated hepatocytes and canal

APA, Harvard, Vancouver, ISO, and other styles

5

Cusack, B. J., Stephan P. Young, Robert E. Vestal, and Richard D. Olson. "Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat." Cancer Chemotherapy and Pharmacology 39, no. 6 (1997): 505–12. http://dx.doi.org/10.1007/s002800050606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nikanjam, Mina, Edmund Capparelli, Jeffrey E. Lancet, Jonathan E. Kolitz, Arthur C. Louie, and Gary J. Schiller. "Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction." Blood 128, no. 22 (2016): 3955. http://dx.doi.org/10.1182/blood.v128.22.3955.3955.

Full text

Abstract:

Abstract Introduction: CPX-351 (Vyxeos) is a novel liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio that has been studied in a phase III clinical trial for secondary acute myeloid leukemia. The current study investigated pharmacokinetic and pharmacodynamic relationships of this liposomal formulation. Methods: CPX-351 pharmacokinetic data from a Phase I study of patients (median age: 62, range 24-81 years) with relapsed and refractory acute myeloid leukemia were used for the analysis. CPX-351 was given as a 90-minute infusion on days 1, 3, and 5 of induction thera

APA, Harvard, Vancouver, ISO, and other styles

7

Alves, Ana Catarina, Daniela Ribeiro, Miguel Horta, José L. F. C. Lima, Cláudia Nunes, and Salette Reis. "A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity." Journal of The Royal Society Interface 14, no. 133 (2017): 20170408. http://dx.doi.org/10.1098/rsif.2017.0408.

Full text

Abstract:

Daunorubicin is extensively used in chemotherapy for diverse types of cancer. Over the years, evidence has suggested that the mechanisms by which daunorubicin causes cytotoxic effects are also associated with interactions at the membrane level. The aim of the present work was to study the interplay between daunorubicin and mimetic membrane models composed of different ratios of 1,2-dimyristoyl- sn -glycero- 3 -phosphocholine (DMPC), sphingomyelin (SM) and cholesterol (Chol). Several biophysical parameters were assessed using liposomes as mimetic model membranes. Thereby, the ability of daunoru

APA, Harvard, Vancouver, ISO, and other styles

8

Albrecht, K. W., S. Leenstra, P. J. M. Bakker, et al. "High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin." Clinical Neurology and Neurosurgery 99 (July 1997): S231. http://dx.doi.org/10.1016/s0303-8467(97)82346-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1184 (2008): 15. http://dx.doi.org/10.2165/00128415-200811840-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 562 (1995): 6. http://dx.doi.org/10.2165/00128415-199505620-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 392 (1992): 5. http://dx.doi.org/10.2165/00128415-199203920-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 398 (1992): 6. http://dx.doi.org/10.2165/00128415-199203980-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 407 (1992): 5. http://dx.doi.org/10.2165/00128415-199204070-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 898 (2002): 6. http://dx.doi.org/10.2165/00128415-200208980-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1263 (2009): 15. http://dx.doi.org/10.2165/00128415-200912630-00046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1243 (2009): 18–19. http://dx.doi.org/10.2165/00128415-200912430-00055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1257 (2009): 17–18. http://dx.doi.org/10.2165/00128415-200912570-00053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 338 (1991): 4. http://dx.doi.org/10.2165/00128415-199103380-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 357 (1991): 6. http://dx.doi.org/10.2165/00128415-199103570-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1297 (2010): 21. http://dx.doi.org/10.2165/00128415-201012970-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1333 (2011): 19. http://dx.doi.org/10.2165/00128415-201113330-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Hempel, Georg, Petra Schulze-Westhoff, Silke Flege, and Joachim Boos. "Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis." Journal of Chromatography B: Biomedical Sciences and Applications 758, no. 2 (2001): 221–28. http://dx.doi.org/10.1016/s0378-4347(01)00185-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1395 (2012): 17–18. http://dx.doi.org/10.2165/00128415-201213950-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1397 (2012): 14. http://dx.doi.org/10.2165/00128415-201213970-00046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 751 (1999): 7. http://dx.doi.org/10.2165/00128415-199907510-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Daunorubicin/mitoxantrone." Reactions Weekly &NA;, no. 1158 (2007): 12. http://dx.doi.org/10.2165/00128415-200711580-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1363 (2011): 16. http://dx.doi.org/10.2165/00128415-201113630-00058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Daunorubicin/pirarubicin." Reactions Weekly &NA;, no. 1366 (2011): 13. http://dx.doi.org/10.2165/00128415-201113660-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1371 (2011): 14. http://dx.doi.org/10.2165/00128415-201113710-00049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Doxorubicin/daunorubicin." Reactions Weekly &NA;, no. 439 (1993): 8. http://dx.doi.org/10.2165/00128415-199304390-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Doxorubicin/daunorubicin." Reactions Weekly &NA;, no. 471 (1993): 8. http://dx.doi.org/10.2165/00128415-199304710-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Daunorubicin liposomal." Reactions Weekly &NA;, no. 814 (2000): 6–7. http://dx.doi.org/10.2165/00128415-200008140-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Daunorubicin liposomal." Reactions Weekly &NA;, no. 829 (2000): 7. http://dx.doi.org/10.2165/00128415-200008290-00018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1399 (2012): 12–13. http://dx.doi.org/10.2165/00128415-201213990-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 373 (1991): 5. http://dx.doi.org/10.2165/00128415-199103730-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 423 (1992): 7. http://dx.doi.org/10.2165/00128415-199204230-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1213 (2008): 16. http://dx.doi.org/10.2165/00128415-200812130-00046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1106 (2006): 10. http://dx.doi.org/10.2165/00128415-200611060-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 898 (2002): 6. http://dx.doi.org/10.2165/00128415-200208980-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Cyclophosphamide/daunorubicin." Reactions Weekly &NA;, no. 1258 (2009): 13. http://dx.doi.org/10.2165/00128415-200912580-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1280 (2009): 18–19. http://dx.doi.org/10.2165/00128415-200912800-00057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 1252 (2009): 19. http://dx.doi.org/10.2165/00128415-200912520-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 292 (1990): 5. http://dx.doi.org/10.2165/00128415-199002920-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Daunorubicin/doxorubicin." Reactions Weekly &NA;, no. 348 (1991): 7. http://dx.doi.org/10.2165/00128415-199103480-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 354 (1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Daunorubicin/mitoxantrone." Reactions Weekly &NA;, no. 1309 (2010): 18. http://dx.doi.org/10.2165/00128415-201013090-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Daunorubicin/idarubicin." Reactions Weekly &NA;, no. 946 (2003): 8–9. http://dx.doi.org/10.2165/00128415-200309460-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1291 (2010): 17. http://dx.doi.org/10.2165/00128415-201012910-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 1294 (2010): 16. http://dx.doi.org/10.2165/00128415-201012940-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Daunorubicin/tretinoin." Reactions Weekly &NA;, no. 1301 (2010): 18. http://dx.doi.org/10.2165/00128415-201013010-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!